Abstract:Ethnopharmacological relevance: Xuebijing injection (XBJ), a Chinese patent medicine that was approved for treating sepsis in China in 2004, consists of Carthamus tinctorius L. (Carthami Flos, hong hua), Paeonia lactiflora Pall. (Paeoniae Radix Rubra, chi shao), Ligusticum chuanxiong Hort. (Chuanxiong Rhizoma, chuan xiong), Salvia miltiorrhiza Bge. (Salviae Miltiorrhizae Radix Et Rhizoma, dan shen) and Angelica sinensis (Oliv.) Diels (Angelicae Sinensis Radix, dang gui). Aim of the study: This study aimed to assess the efficacy and safety of XBJ combined with routine treatment (RT) for treating sepsis through systematic review and meta-analysis. Materials and methods: Databases including Embase, PubMed, the Cochrane Central Register of Controlled Trials, China National Knowledge Infrastructure (CNKI), Chinese Science and Technology Journal Database (VIP) and the Wanfang database were searched from inception to June 6, 2017 to collect relevant RCTs comparing XBJ combined with RT and RT alone for sepsis. The primary clinical outcomes were 28-day mortality and mortality during treatment. The secondary outcomes of our study included APACHE Ⅱ scores, WBC counts, body temperature, and adverse events or reactions. We excluded low-quality studies (Jadad score < 3) and calculated risk ratios (RR) for primary outcomes with fixed effects models. We assessed quality of evidence using the grading of recommendations assessment, development, and evaluation (GRADE) approach. Results: We identified 1602 records, and 16 RCTs (1144 patients) were included. Moderate-quality evidence suggested that combined therapy reduced 28-day mortality (934/1144, RR 0.62, 95% CI 0.51-0.76 P < 0.000 01, I2 = 0%), APACHE Ⅱ scores (792/1144, MD -3.53, 95% CI -4.49 to -2.54; P < 0.000 01, I2 = 59%) and body temperature (362/1144, MD -0.43, 95% CI -0.55 to -0.31; P < 0.000 01, I2 = 0%). Very low-quality evidence showed that WBC count improved with combined medication at high dosages (one study included, 40/1144, MD -8.00, 95% CI -10.18 to -5.82), but there was no reduction at moderate dosages (230/1144, MD -2.38, 95% CI -5.01 to 0.25; P = 0.08, I2 = 70%). However, moderate-quality evidence indicated positive results with low dosages (142/1144, MD -2.88, 95% CI -3.79 to -1.96; P < 0.000 01, I2 = 0%). Nevertheless, due to the insufficient number of studies and the poor quality of the current evidence, more studies of dose-effect relationships and safety concerns of XBJ are needed. Low-quality evidence showed no risk difference for mortality during treatment (210/1144, RR 0.65, 95% CI 0.36-1.17; P = 0.15, I2 = 0%). Conclusions: This study suggested that supplementation with XBJ in addition to regular treatment may improve the 28-day mortality rate, APACHE Ⅱ scores, WBC count and body temperature of sepsis patients without serious adverse events, but it may not reduce mortality during treatment, revealing a specific, remote effect of traditional Chinese medicine. However, given the high risk of bias and the low quality of the included trials, we may be unable to draw any conclusions about its routine use. Rigorously designed, multicentre, large-scale, methodologically sound trials are warranted.

Marked Reduction in 28-day Mortality Among Elderly Patients with Severe Community-acquired Pneumonia: Post Hoc Analysis of a Large Randomized Controlled Trial

XueBiJing Injection Versus Placebo for Critically Ill Patients with Severe Community-Acquired Pneumonia: A Randomized Controlled Trial.

Weaker Response to XueBiJing Treatment in Severe Community-Acquired Pneumonia Patients with Higher Body Mass Index or Hyperglycemia: A Post Hoc Analysis of a Randomized Controlled Trial

Could Xuebijing Injection Reduce the Mortality of Severe Pneumonia Patients? A Systematic Review and Meta-Analysis

Effect of an Herbal-Based Injection on 28-Day Mortality in Patients With Sepsis

LATE-BREAKING ABSTRACT: Intravenous Infusion of Chinese Medicine Xuebijing Significantly Improved Clinical Outcome in Severe Pneumonia Patients in a Multiple Center Randomized Controlled Clinical Trials

Xuebijing injection in the treatment of severe pneumonia: study protocol for a randomized controlled trial

Efficacy and Safety of Xuebijing Injection for Severe Pneumonia: A Protocol for A Systematic Review and Meta-Analysis

Clinical efficacy and safety evaluation of Xuebijing on severe pneumonia

Efficacy and safety of Xuebijing injection (a Chinese patent) for sepsis: A meta-analysis of randomized controlled trials

Intravenous Infusion of Chinese Medicine Xuebijing for Patients with Severe Pneumonia: a Multicenter, Randomised, Double-Blind Controlled Trial

Clinical efficacy of Xuebijing injection for the treatment of sepsis: A retrospective cohort study

The prediction of lymphocyte count and neutrophil count on the efficacy of Xuebijing adjuvant treatment for severe community-acquired pneumonia: a post hoc analysis of a randomized controlled trial

Efficacy and safety of Xuebijing injection and its influence on immunomodulation in acute exacerbations of chronic obstructive pulmonary disease: study protocol for a randomized controlled trial.

Xuebijing injection, a Chinese patent medicine, against severe pneumonia: Current research progress and future perspectives

Effect of traditional Chinese preparation Xuebijing on inflammatory markers in patients with ventilator-associated pneumonia

Cost Effectiveness of Different Initial Antimicrobial Regimens for Elderly Community-Acquired Pneumonia Patients in General Ward.

Clinical Effect of Antibiotic Therapy in The Treatment of Severe Pneumonia in Elderly Patients

[Effect of Xuebijing Injection Treatment on Acute Respiratory Distress Syndrome: a Multicenter Prospective Randomized Control Clinical Trial].

Efficacy of Xuebijing Injection for Sepsis (EXIT-SEP): Protocol for a Randomised Controlled Trial

Disease burden and prognostic factors for clinical failure in elderly community acquired pneumonia patients